Browse the corpus

Digoxin, a cardiac glycoside derived from Digitalis lanata, is often used when first-line agents are ineffective. This medication was approved by the US Food and Drug Administration and is now primarily reserved for treating mild-to-moderate heart conditions, particularly heart failure and chronic atrial fibrillation. Digoxin helps control ventricular response rates and improves cardiac output. The key mechanisms include a positive inotropic effect that enhances myocardial contraction and AV node inhibition, which slows the heart rate by prolonging the AV node's refractory period. While historically used for off-label indications, including fetal demise induction, concerns over efficacy and safety have limited such uses. This activity provides essential knowledge and practical tools for the optimal administration of digoxin, covering its indications, contraindications, mechanism of action, adverse effects, dosing, pharmacokinetics, interactions, and toxicity. This activity also highlights the critical role of the interprofessional healthcare team in managing digoxin therapy by enhancing their understanding of its complex pharmacology and potential adverse effects through evidence-based knowledge. In addition, this activity equips healthcare professionals to enhance the overall management of digoxin by customizing treatments, delivering safe and effective care, and supporting individualized therapy. This activity also fosters well-informed decisions and precise dosage adjustments, empowering clinicians to achieve the best patient outcomes. Objectives: Identify the indications for digoxin use in patients with heart failure and atrial fibrillation, recognizing when it is appropriate as part of a comprehensive treatment plan. Implement evidence-based guidelines for dosing and monitoring digoxin, ensuring appropriate adjustments for patients with varying clinical presentations. Apply pharmacokinetic principles to determine the appropriate digoxin dose based on the patient’s renal function and comorbidities. Collaborate with specialists, including cardiologists and nephrologists, to optimize digoxin therapy and manage complications such as arrhythmias and renal dysfunction. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose The most common signs of digoxin toxicity include nausea, vomiting, anorexia, and fatigue. Overdose can lead to life-threatening arrhythmias or malignant hyperkalemia.[22] Concerns regarding digoxin's association with increased mortality have been raised, as evidence suggests it may elevate mortality risks. Given its narrow therapeutic index, digoxin's administration is highly influenced by drug-drug interactions and comorbid conditions. Bradycardia is commonly observed in digoxin toxicity. Neurological symptoms, such as confusion and weakness, may occur as the drug redistributes to the central nervous system. In cases of chronic toxicity, neurological manifestations can include lethargy, delirium, and generalized weakness. Visual disturbances may include xanthopsia (yellow vision), diplopia, and photophobia.[24] Hyperkalemia is a significant marker of toxicity, while hypomagnesemia, hypokalemia, and hypercalcemia can increase susceptibility to digoxin's effects. Loop diuretics often contribute to hypokalemia, further amplifying the risk of toxicity. Evaluation of renal function is crucial and should include measurements of blood urea nitrogen (BUN), creatinine, and urine output. An ECG should be obtained, as typical findings include premature ventricular contractions, bradycardia, atrial tachyarrhythmias with AV block, ventricular bigeminy, ventricular tachycardia, and ventricular fibrillation. Bidirectional ventricular tachycardia, though rare, is highly suggestive of digoxin toxicity and is characterized by beat-to-beat alternation in the QRS axis.[25][26] Management of Overdose For life-threatening hyperkalemia, treatment should be initiated with glucose and insulin. Activated charcoal may be administered in cases of acute overdose to reduce the elimination half-life of digoxin.[27] Ventricular arrhythmias can be treated with lidocaine or phenytoin. In the event of an overdose, digoxin immune fab is the recommended reversal agent. The following conditions indicate the use of digoxin immune fab: Any life-threatening digoxin-related dysrhythmia Refractory hyperkalemia Serum digoxin concentration greater than 15 ng/mL at any time or above 10 ng/mL 6 hours post-ingestion Acute ingestion of 10 mg in adults Acute ingestion of 4 mg in children

For life-threatening hyperkalemia, treatment should be initiated with glucose and insulin. Activated charcoal may be administered in cases of acute overdose to reduce the elimination half-life of digoxin.[27] Ventricular arrhythmias can be treated with lidocaine or phenytoin. In the event of an overdose, digoxin immune fab is the recommended reversal agent. The following conditions indicate the use of digoxin immune fab: Any life-threatening digoxin-related dysrhythmia Refractory hyperkalemia Serum digoxin concentration greater than 15 ng/mL at any time or above 10 ng/mL 6 hours post-ingestion Acute ingestion of 10 mg in adults Acute ingestion of 4 mg in children Chronic elevation of serum digoxin concentration with altered mental status, dysrhythmias, or severe gastrointestinal symptoms

An overdose of digoxin can lead to severe arrhythmias and malignant hyperkalemia. The association between digoxin use and increased mortality has raised significant concerns among researchers, as it appears to elevate the risk of death. Due to these risks, digoxin therapy requires oversight from an interprofessional healthcare team, including clinicians, specialists, advanced-practice providers, nurses, and pharmacists. This healthcare team must collaborate, share information, and coordinate care to optimize therapy and prevent adverse effects. Digoxin has a narrow therapeutic index, and its administration is influenced by drug-drug interactions and comorbidities. The management of digoxin toxicity primarily involves supportive therapy, including IV hydration and electrolyte repletion.[28] Timely and specific intervention from the medical team is essential, as patients may face a significant mortality risk without it. If digoxin toxicity is confirmed, following the assessment of serum digoxin levels and the ECG, the clinician should promptly request a digoxin immune fab from the pharmacy and review the patient's medication profile for potential drug interactions. This approach requires the collaboration of the entire medical team. Additionally, consultation with a nephrologist should be considered if emergent hemodialysis is indicated. Supportive care, including IV hydration and electrolyte repletion, is essential. Involving a toxicologist for specialized guidance may also be beneficial, and for international overdose cases, a psychiatry consultation should be considered to address any underlying psychological issues. The patient may require admission to the medical intensive care unit (MICU) or cardiac care unit (CCU) under the supervision of a critical care physician. An interprofessional team approach, with communication among clinicians, specialists, pharmacists, and nurses, is crucial to minimizing toxicity and improving patient outcomes related to digoxin therapy.